Investor Relations
Company Profile
LakeShore Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Shingles, influenza, Coronavirus and other infectious diseases. LakeShore Biopharma operates in China, Singapore, the United States, the United Arab Emirates, and the Philippines. The company currently has over 800 employees, led by a management team that combines rich local expertise and global vision in the vaccine and pharmaceutical industry.
News Releases
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and U
2024-12-19 15:59:46
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in C
2024-12-12 16:14:21
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regul
2024-11-07 16:16:46
2024-10-29 16:17:49
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJ
2024-10-25 16:19:14
Events
2024-04-19 16:38:18
2023-09-07 21:11:57
2023-08-15 21:08:07
2023-07-26 21:07:32
2023-05-23 21:06:10